These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 33684714)

  • 41. Mechanistic selectivity investigation and 2D-QSAR study of some new antiproliferative pyrazoles and pyrazolopyridines as potential CDK2 inhibitors.
    Hassan GS; Georgey HH; Mohammed EZ; George RF; Mahmoud WR; Omar FA
    Eur J Med Chem; 2021 Jun; 218():113389. PubMed ID: 33784602
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development of newly synthesised quinazolinone-based CDK2 inhibitors with potent efficacy against melanoma.
    Mohammed ER; Elmasry GF
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):686-700. PubMed ID: 35139719
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Design and synthesis of novel isatin-based derivatives targeting cell cycle checkpoint pathways as potential anticancer agents.
    Yousef MA; Ali AM; El-Sayed WM; Qayed WS; Farag HHA; Aboul-Fadl T
    Bioorg Chem; 2020 Dec; 105():104366. PubMed ID: 33212312
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Design, synthesis and molecular docking studies of thymol based 1,2,3-triazole hybrids as thymidylate synthase inhibitors and apoptosis inducers against breast cancer cells.
    Alam MM; Malebari AM; Syed N; Neamatallah T; Almalki ASA; Elhenawy AA; Obaid RJ; Alsharif MA
    Bioorg Med Chem; 2021 May; 38():116136. PubMed ID: 33894490
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cytotoxicity, Docking Study of New Fluorinated Fused Pyrimidine Scaffold: Thermal and Microwave Irradiation Synthesis.
    Alnaja AMA; Farghaly TA; El-Zahabi HSA; Shaaban MR
    Med Chem; 2021; 17(5):501-518. PubMed ID: 31840613
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Design, synthesis and biological evaluation of 1,3-diphenyl-1H-pyrazole derivatives containing benzimidazole skeleton as potential anticancer and apoptosis inducing agents.
    Reddy TS; Kulhari H; Reddy VG; Bansal V; Kamal A; Shukla R
    Eur J Med Chem; 2015 Aug; 101():790-805. PubMed ID: 26231080
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Design, synthesis and biological study of novel pyrido[2,3-d]pyrimidine as anti-proliferative CDK2 inhibitors.
    Ibrahim DA; Ismail NS
    Eur J Med Chem; 2011 Dec; 46(12):5825-32. PubMed ID: 22000924
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations.
    Chohan TA; Chen JJ; Qian HY; Pan YL; Chen JZ
    Mol Biosyst; 2016 Apr; 12(4):1250-68. PubMed ID: 26883408
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.
    Li Y; Gao W; Li F; Wang J; Zhang J; Yang Y; Zhang S; Yang L
    Mol Biosyst; 2013 Sep; 9(9):2266-81. PubMed ID: 23864105
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Series of Isatin-Hydrazones with Cytotoxic Activity and CDK2 Kinase Inhibitory Activity: A Potential Type II ATP Competitive Inhibitor.
    Al-Salem HS; Arifuzzaman M; Alkahtani HM; Abdalla AN; Issa IS; Alqathama A; Albalawi FS; Rahman AFMM
    Molecules; 2020 Sep; 25(19):. PubMed ID: 32992673
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Application of hydrazino and hydrazido linkers to connect benzenesulfonamides with hydrophilic/phobic tails for targeting the middle region of human carbonic anhydrases active site: Selective inhibitors of hCA IX.
    Allam HA; Fahim SH; F Abo-Ashour M; Nocentini A; Elbakry ME; Abdelrahman MA; Eldehna WM; Ibrahim HS; Supuran CT
    Eur J Med Chem; 2019 Oct; 179():547-556. PubMed ID: 31276899
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synthesis, biological evaluation, and molecular docking studies of N-((1,3-diphenyl-1H-pyrazol-4-yl)methyl)aniline derivatives as novel anticancer agents.
    Huang XF; Lu X; Zhang Y; Song GQ; He QL; Li QS; Yang XH; Wei Y; Zhu HL
    Bioorg Med Chem; 2012 Aug; 20(16):4895-900. PubMed ID: 22819191
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Synthesis, biological evaluation and molecular docking of benzimidazole grafted benzsulfamide-containing pyrazole ring derivatives as novel tubulin polymerization inhibitors.
    Wang YT; Shi TQ; Zhu HL; Liu CH
    Bioorg Med Chem; 2019 Feb; 27(3):502-515. PubMed ID: 30606674
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In Silico and In Vitro Evaluations of Fluorophoric Thiazolo-[2,3-b]quinazolinones as Anti-cancer Agents Targeting EGFR-TKD.
    Mir SA; Dash GC; Meher RK; Mohanta PP; Chopdar KS; Mohapatra PK; Baitharu I; Behera AK; Raval MK; Nayak B
    Appl Biochem Biotechnol; 2022 Oct; 194(10):4292-4318. PubMed ID: 35366187
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Design, synthesis, and biological evaluation of novel pyrimidine derivatives as CDK2 inhibitors.
    Ibrahim DA; El-Metwally AM
    Eur J Med Chem; 2010 Mar; 45(3):1158-66. PubMed ID: 20045222
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Design, synthesis, docking and QSAR study of substituted benzimidazole linked oxadiazole as cytotoxic agents, EGFR and erbB2 receptor inhibitors.
    Akhtar MJ; Siddiqui AA; Khan AA; Ali Z; Dewangan RP; Pasha S; Yar MS
    Eur J Med Chem; 2017 Jan; 126():853-869. PubMed ID: 27987485
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synthesis and molecular modeling of new benzimidazoles as glutathione S-transferase inhibitors and anticancer agents.
    Abd El-Karim SS; Anwar MM; Zaki ER; Elseginy SA; Nofal ZM
    Future Med Chem; 2018 Jan; 10(2):157-181. PubMed ID: 29235906
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular simulation studies on the binding selectivity of 2-anilino-4-(thiazol-5-yl)-pyrimidines in complexes with CDK2 and CDK7.
    Chohan TA; Qian HY; Pan YL; Chen JZ
    Mol Biosyst; 2016 Jan; 12(1):145-61. PubMed ID: 26565382
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A New CDK2 Inhibitor with 3-Hydrazonoindolin-2-One Scaffold Endowed with Anti-Breast Cancer Activity: Design, Synthesis, Biological Evaluation, and In Silico Insights.
    Al-Sanea MM; Obaidullah AJ; Shaker ME; Chilingaryan G; Alanazi MM; Alsaif NA; Alkahtani HM; Alsubaie SA; Abdelgawad MA
    Molecules; 2021 Jan; 26(2):. PubMed ID: 33466812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.